PT1411926E - Inibidores de integrina para o tratamento de doencas oftalmicas - Google Patents

Inibidores de integrina para o tratamento de doencas oftalmicas

Info

Publication number
PT1411926E
PT1411926E PT02748841T PT02748841T PT1411926E PT 1411926 E PT1411926 E PT 1411926E PT 02748841 T PT02748841 T PT 02748841T PT 02748841 T PT02748841 T PT 02748841T PT 1411926 E PT1411926 E PT 1411926E
Authority
PT
Portugal
Prior art keywords
integrine
inhibitors
treatment
ophthalmic diseases
ophthalmic
Prior art date
Application number
PT02748841T
Other languages
English (en)
Inventor
Matthias Wiesner
Hans Markus Bender
Haunschild Jutta
Lang Ulrich
Friedlander Martin
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT1411926E publication Critical patent/PT1411926E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT02748841T 2001-08-01 2002-07-03 Inibidores de integrina para o tratamento de doencas oftalmicas PT1411926E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01

Publications (1)

Publication Number Publication Date
PT1411926E true PT1411926E (pt) 2005-10-31

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02748841T PT1411926E (pt) 2001-08-01 2002-07-03 Inibidores de integrina para o tratamento de doencas oftalmicas

Country Status (20)

Country Link
US (2) US20040198644A1 (pt)
EP (1) EP1411926B1 (pt)
JP (1) JP2005504757A (pt)
KR (1) KR20040028966A (pt)
CN (1) CN1536998A (pt)
AR (1) AR036199A1 (pt)
AT (1) ATE296628T1 (pt)
AU (1) AU2002319282B2 (pt)
BR (1) BR0211604A (pt)
CA (1) CA2456076C (pt)
DE (1) DE60204466T2 (pt)
DK (1) DK1411926T3 (pt)
ES (1) ES2243744T3 (pt)
HU (1) HUP0401605A3 (pt)
MX (1) MXPA04000839A (pt)
PL (1) PL207175B1 (pt)
PT (1) PT1411926E (pt)
RU (1) RU2311177C2 (pt)
WO (1) WO2003013511A1 (pt)
ZA (1) ZA200401598B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
JP4598399B2 (ja) 2002-02-04 2010-12-15 エラン ファーマ インターナショナル，リミティド 表面安定剤としてリゾチームを有するナノ粒子組成物
AR056320A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
JP5359879B2 (ja) 2007-11-16 2013-12-04 宇部興産株式会社 ベンズアゼピノン化合物
WO2010113958A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
CA3007198A1 (en) * 2015-12-04 2017-06-08 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
JP7213804B2 (ja) * 2016-11-08 2023-01-27 ブリストル－マイヤーズ スクイブ カンパニー αＶインテグリンアンタゴニストとしてのインダゾール誘導体
KR102307767B1 (ko) * 2019-03-11 2021-10-01 서울대학교병원 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313146C (zh) * 1995-08-14 2007-05-02 斯克里普斯研究学院 用于抑制αvβ5介导的血管生成的方法和组合物
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
PT951295E (pt) * 1996-05-31 2010-07-29 Scripps Research Inst COMPOSIÎES PARA UTILIZAÆO NA INIBIÆO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3
WO1997045137A1 (en) * 1996-05-31 1997-12-04 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
WO1999045909A2 (en) * 1998-03-13 1999-09-16 Centaur Pharmaceuticals Use of nitrone compounds for the inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
CA2456076A1 (en) 2003-02-20
RU2004106527A (ru) 2005-07-10
JP2005504757A (ja) 2005-02-17
US20040198644A1 (en) 2004-10-07
AU2002319282B2 (en) 2007-06-28
AR036199A1 (es) 2004-08-18
PL207175B1 (pl) 2010-11-30
HUP0401605A2 (hu) 2004-11-29
KR20040028966A (ko) 2004-04-03
DE60204466D1 (de) 2005-07-07
WO2003013511A1 (en) 2003-02-20
MXPA04000839A (es) 2004-05-14
BR0211604A (pt) 2004-08-24
ES2243744T3 (es) 2005-12-01
CN1536998A (zh) 2004-10-13
ZA200401598B (en) 2004-11-17
HUP0401605A3 (en) 2012-09-28
PL367959A1 (en) 2005-03-07
US20060287225A1 (en) 2006-12-21
US7645736B2 (en) 2010-01-12
EP1411926A1 (en) 2004-04-28
DE60204466T2 (de) 2006-04-27
EP1411926B1 (en) 2005-06-01
CA2456076C (en) 2011-08-23
ATE296628T1 (de) 2005-06-15
DK1411926T3 (da) 2005-08-29
RU2311177C2 (ru) 2007-11-27

Similar Documents

Publication Publication Date Title
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
CY2014019I2 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
PT1392292E (pt) Piranoindazoles e sua utilizacao para o tratamento de glaucoma
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
FIU20060389U0 (fi) Luusairauksien hoito
NO20035156L (no) Fremgangsmåter for brønnbehandling
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
AP2005003341A0 (en) 2-(1H-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatmentof ophthalmic diseases
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
HUP0400024A3 (en) Combination for treatment of neoplastic diseases
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
PT1268482E (pt) Piranoindois para o tratamento de glaucoma
PT1282599E (pt) Derivados dissulfureto uteis para tratar doencas alergicas
PT1381620E (pt) Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes
PT1225890E (pt) Rivastigmina para o tratamento de doencas oculares
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
ATE272619T1 (de) Anilin-disulfid-derivate zur behandlung allergischer erkrankungen
IS8498A (is) Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma